Precision oncology involves identifying drugs that will effectively treat a tumor and then prescribing an optimal clinical treatment regimen. However, most first-line chemotherapy drugs do not have biomarkers to guide their application. For molecularly targeted drugs, using the genomic status of a drug...
FDA-Approved Targeted Therapies in Oncology: Applications in Precision MedicineTargeted therapies serve as a foundation for precision medicine. Unlike traditional chemotherapy which affects all cells in the body, the drugs used in targeted therapies block only the growth of cancer cells by interfering ...
Rudalska et al. describe a novel class of p38α inhibitors with increased target residence time. They explore the drugs’ specificity, pharmacokinetics and toxicity profile and show that they are efficacious in the context of colorectal cancer. ...
Simple Summary: Precision oncology is the use of anticancer drugs to specifically inhibit the function of aberrant oncogenic proteins driving a patient's t... IW Song,HH Vo,YS Chen,... - 《Cancers》 被引量: 0发表: 2023年 Physiologically‐based pharmacokinetic modelling to predict oprozomib CYP3...
Similarly LY3164530 target both c-MET and EGFR and show more efficiency than emibetuzumab or drugs such as volitinib, gefitinib, SAR125844 which is triazolopyridazne derivative, Tepotinib, and capmatinib [77, 78]. One of the main causes of mortality in CRC is liver metastasis. In this...
(NSCLC) patients with frameshift mutations.73In addition, ICBs can also strengthen the immune response to frameshift neoantigens. The frameshift mutation in CALR elicits both CD4+and CD8+T cell responses, which are inhibited by the expression of PD-1 or CTLA4. Importantly, blocking PD-1 and ...
The use of targeted therapies in gastrointestinal oncology In recent years, several drugs have been approved that specifically target molecular changes in tumour cells. For patients with gastrointestinal cancer, th... S Lange - 《Dmw Deutsche Medizinische Wochenschrift》 被引量: 0发表: 2024年 [Targ...
Several Trop2-targeted drugs are currently under development, including antibodies, ADCs, and combination therapies, with ADCs at the forefront of cancer therapy and precision medicine. The FDA has approved SG for the treatment of TNBC and HR+/HER2-breast cancer patients. There are several Trop2...
Aptamer technology as a drug delivery agent has advantages over antibodies. Therefore, aptamers have been conjugated with chemotherapy drugs or other cancer treatment agents through physical or chemical. Due to the lower molecular weight of conjugation aptamer-drug conjugates (AptDC), led to faster and...
involving a wide range of anticancer drugs for treatment, palliation, symptom alleviation, and quality of life improvement, includes cytotoxic chemotherapy, hormonal agents, targeted therapy, and antitumor immunotherapy5,6. Cytotoxic chemotherapy inhibits the survival of actively proliferating cells by disr...